On May 12, 2021, the Board of Directors of Flexion Therapeutics, Inc. appointed Frederick W. Driscoll as, principal financial officer, and principal accounting officer, effective upon the termination of Mr. Arkowitz’s employment with Flexion. Mr. Driscoll, served as Chief Financial Officer of Flexion from 2013 to 2017. Prior to joining Flexion in 2013, Mr. Driscoll served as Chief Financial Officer at Novavax, Inc; Chief Executive Officer at Genelabs Technologies, Inc., from 2008 to 2009, and as its Chief Financial Officer from 2007 to 2008.